Analyst Expectations For Guardant Health's Future
Portfolio Pulse from Benzinga Insights
Analyst ratings for Guardant Health (NASDAQ:GH) show a mix of bullish and somewhat bullish outlooks, with no changes in the last 30 days. The average 12-month price target is now $38.8, down from $47.20, indicating a 17.8% decrease. Analysts from Piper Sandler, JP Morgan, Canaccord Genuity, and Goldman Sachs have lowered their price targets. Guardant Health, a leader in liquid-based cancer tests, has shown a revenue growth rate of 22.19% as of December 31, 2023, but struggles with profitability and debt management.
April 05, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Guardant Health's mixed analyst ratings and lowered price targets reflect cautious optimism. Despite revenue growth, profitability and debt management issues persist.
The mixed analyst ratings and recent adjustments to price targets suggest a cautious but somewhat optimistic outlook for Guardant Health. The significant revenue growth indicates strong business performance, yet the company's challenges with profitability and high debt levels may temper investor enthusiasm in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100